SmartBrief > Health Care > AANP SmartBrief > Related Stories

FDA advisers endorse Remicade for children with ulcerative colitis

The benefit-risk profile of Johnson & Johnson's Remicade supports its approval for treating ulcerative colitis in children for whom other medications don't work, an FDA advisory panel concluded. However, panelists said additional data are warranted on the risk of cancer, particularly hepatosplenic T-cell lymphoma, and serious infections associated with Remicade and similar drugs.

Share

This news summary appeared in AANP SmartBrief on 07/22/2011
Click here to view the full issue.


View the original article:
Wall Street Journal, The

Want to see more news summaries?
Sign up for AANP SmartBrief
AANP SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news summaries like the one to the left
Sign up:
About SmartBrief
SmartBrief is the leading online publisher of targeted business news and information by industry. By combining technology and editorial expertise, SmartBrief filters thousands of sources daily to deliver the most relevant industry news in partnership with more than 180 trade associations, professional societies nonprofits and corporate entities